Acute Rhinosinusitis
Conditions
Brief summary
Seasonal and perennial allergic rhinitis, acute rhino sinusitis, and nasal polyposis are examples of common inflammatory disorders of the airway that significantly reduce patient health and quality of life. Intranasal corticosteroids are advised as part of treatment plans for each of these illnesses since they help to reduce inflammation and thus symptoms. Objective In order to assess the effectiveness and safety of a new nano formulation of Mometasone furoate nano-nasal spray (FM-NNS) for the treatment of allergic rhinitis. Mometasone Furoate Nano-nasal spray (FM-NNS) was compared with commercial available nasal spray named as MFNS.
Detailed description
Background Seasonal and perennial allergic rhinitis, acute rhino sinusitis, and nasal polyposis are examples of common inflammatory disorders of the airway that significantly reduce patient health and quality of life. Intranasal corticosteroids are advised as part of treatment plans for each of these illnesses since they help to reduce inflammation and thus symptoms. Objective In order to assess the effectiveness and safety of a new nano formulation of Mometasone furoate nano-nasal spray (FM-NNS) for the treatment of allergic rhinitis. Mometasone Furoate Nano-nasal spray (FM-NNS) was compared with commercial available nasal spray named as MFNS.
Interventions
DRUGMometasone Nasal 50 Mcg/Inh Nasal Spray
Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.
DEVICENasal spray
device can work properly for actuation during trials
Sponsors
Saffron Pharma
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
10 Years to 50 Years
Inclusion criteria
1. Children and adults of age (10-50) who had a diagnosis of rhinitis 2. Ability and willingness to understand and provide informed consent.
Exclusion criteria
1. Known current pregnancy. 2. Current hospitalization. 3. Unable to complete online questionnaires or adhere to study requirements. 4. Kidney failure or dialysis; severe liver disease or cirrhosis. 5. Any parathyroid conditions. 6. Known current pregnancy. 7. History of SARS-CoV-2 infection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| congestion | 3 weeks | The primary end outcomes were change from baseline in the subject's congestion and/or blockage score averaged throughout the first month of treatment and change from baseline in the physician's assessment of Allergic rhinitis. |
Countries
Pakistan
Outcome results
None listed